Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

8(88.9%)

Phase 1

1(11.1%)

9Total

N/A(8)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05055297Not ApplicableRecruiting

SELUTION4BTK Trial

Role: lead

NCT04859985Not ApplicableActive Not Recruiting

The SELUTION DeNovo Study

Role: lead

NCT05132361Not ApplicableActive Not Recruiting

SELUTION4SFA Trial

Role: lead

NCT04280029Not ApplicableActive Not Recruiting

SELUTION SLR™ 014 In-stent Restenosis

Role: lead

NCT05946629Not ApplicableRecruiting

SELUTION 4 De Novo Small Vessel IDE Trial

Role: lead

NCT04776434Not ApplicableActive Not Recruiting

SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study

Role: lead

NCT04327609Not ApplicableCompleted

SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications

Role: lead

NCT05362994Not ApplicableUnknown

Selution Sirolimus-eluting Balloon for Internal Pudendal-penile Artery Disease-related Erectile Dysfunction

Role: collaborator

NCT02941224Phase 1Completed

First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries

Role: lead

All 9 trials loaded